Skip to main content

Pipeline

Target categories

We select targets with clear opportunity for a precision medicine strategy to address three target categories in what we consider “therapeutic white spaces” of underserved populations.

Validated oncogene targets

  • Best-in-class opportunities
  • Validated targets with drugs approved or in development
  • Superior selectivity for mutant forms of the target in head-to-head studies
  • Optimized drug design to achieve Target Product Profiles addressing patient needs

 

Undruggable targets

  • First-in-class opportunities
  • New un-labelled patient populations
  • Biologically de-risked drivers with no drug candidates known
  • Transcription factors; synthetic lethals; others

Novel cancer targets

  • First-in-class opportunities
  • New un-labelled patient populations
  • New tumor-specific drivers, including targets synthetically lethal with loss-of-heterozygosity (LOH) events
  • Potential for deeper response vs. traditional oncogenes

Pipeline

Target

Discovery

Phase 1

Phase 2

Phase 3

STX-478

Mut-Sel H1047 PI3Kα

STX-721

Mut-Sel EGFR Exon 20 insertion

Other

Best-in-class Discovery Programs Against Validated Oncogene Targets

First-in-Class Discovery Programs Against Undruggable Targets

First-in-Class Discovery Programs Against Novel Cancer Targets

Partners

Since 2022